• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by OS Therapies Incorporated

    8/28/24 4:30:09 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSTX alert in real time by email
    SC 13G 1 tm2422947d1_sc13g.htm SC 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

    OS THERAPIES INCORPORATED

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    68764Y207

     

    (CUSIP Number)

     

    August 2, 2024

     

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

     

    *               The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     

    Page 1 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    1.NAMES OF REPORTING PERSONS

     

    Thomas A. Satterfield, Jr.

     

    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)¨
    (b)¨

     

    3.SEC USE ONLY

     

    4.CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.SOLE VOTING POWER

     

    50,000

     

    6.SHARED VOTING POWER

     

    1,244,989

     

    7.SOLE DISPOSITIVE POWER

     

    50,000

     

    8.SHARED DISPOSITIVE POWER

     

    1,244,989

     

    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,294,989

     

    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

     

    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.20%*

     

    12.TYPE OF REPORTING PERSON

     

    IN

      

    * Based on 20,884,575 shares of common stock of the issuer outstanding as of August 14, 2024, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024.

     

    Page 2 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    SCHEDULE 13G

     

    Item 1.

     

    (a)Name of Issuer:

     

    OS Therapies Incorporated

     

    (b)Address of Issuer's Principal Executive Offices:

     

    115 Pullman Crossing Road, Suite 103

    Grasonville, Maryland 21638

     

    Item 2.

     

    (a)Name of Person Filing:

     

    Thomas A. Satterfield, Jr.

     

    (b)Address of Principal Business Office or, if none, Residence:

     

    Thomas A. Satterfield, Jr.

    15 Colley Cove Drive

    Gulf Breeze, Florida 32561

     

    (c)Citizenship:

     

    Incorporated by reference from Item 4 of the Cover Page.

     

    (d)Title of Class of Securities:

     

    Incorporated by reference from the Cover Page.

     

    (e)CUSIP Number:

     

    Incorporated by reference from the Cover Page.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Incorporated by reference from Item 9 of the Cover Page.

     

    (b)Percent of class:

     

    Incorporated by reference from Item 11 of the Cover Page.

     

    Page 3 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    Incorporated by reference from Item 5 of the Cover Pages.

     

    (ii)Shared power to vote or to direct the vote

     

    Incorporated by reference from Item 6 of the Cover Pages.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    Incorporated by reference from Item 7 of the Cover Pages.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    Incorporated by reference from Item 8 of the Cover Pages.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 50,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 112,500 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 1,082,489 shares are held by Satterfield Vintage Investments, L.P. Tomsat Investment & Trading Co., Inc. and A.G. Family L.P. jointly own a majority of Satterfield Vintage Investments, L.P.’s equity, and Tomsat Investment & Trading Co., Inc. is the general partner of Satterfield Vintage Investments, L.P.

      

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Page 4 of 4 Pages 

     

    CUSIP No. 68764Y207 13G  

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      August 28, 2024
      Date
       
      /s/ Thomas A. Satterfield, Jr.
      Thomas A. Satterfield, Jr.

     

     

    Get the next $OSTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSTX

    DatePrice TargetRatingAnalyst
    4/2/2025$19.00Buy
    Lake Street
    More analyst ratings

    $OSTX
    SEC Filings

    View All

    SEC Form 10-Q filed by OS Therapies Incorporated

    10-Q - OS Therapies Inc (0001795091) (Filer)

    5/18/26 6:02:31 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by OS Therapies Incorporated

    NT 10-Q - OS Therapies Inc (0001795091) (Filer)

    5/15/26 4:15:58 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OS Therapies Inc (0001795091) (Filer)

    4/30/26 4:06:12 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

    75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated clinical efficacy data being added to regulatory dossiers as Company seeks early market authorizations in U.S., U.K., Europe and Australia in 2nd half of 2026EMA and Australia TGA (TGA) alignment achieved on early Q4-2026 3-year overall survival data, supported by biomarker data, as key approvable clinical efficacy endpointUpcoming U.S. FDA and U.K. MHRA meetings seek alignment with EMA and TGA on Phase 2b 3-year overall survival and biomarker data to support early market access Conf

    6/2/26 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

    The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarcoma during the 2026 American Society of Clinical Oncologists (ASCO) Annual Meeting being held from May 28, 2026 to June 2, 2026.New York, New York and Rockville, Maryland--(Newsfile Corp. - May 29, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced the publication of four articles related to OST-HER2 and/or Osteosarcoma in Drug Discovery World.Looking back to see forward: The future of

    5/29/26 7:20:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences

    ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference: Data PresentationNew York, New York and Rockville, Maryland--(Newsfile Corp. - May 26, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, announced that it will attend upcoming medical, financial and scientific conferences:American Society of Clinical Oncologists 2026Where: Chicago, ILWhen: May 29, 2026 to June 2, 2026What: 2.5-year overall survival data announcementJefferies Global Healthcare Conference 2

    5/26/26 7:40:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 5 filed by Romness Paul A.

    5/A - OS Therapies Inc (0001795091) (Issuer)

    5/15/26 6:30:02 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mckean-Dieser Avril Suzette

    4 - OS Therapies Inc (0001795091) (Issuer)

    2/13/26 4:43:41 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Search Theodore F.

    4 - OS Therapies Inc (0001795091) (Issuer)

    2/13/26 4:43:05 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on OS Therapies with a new price target

    Lake Street initiated coverage of OS Therapies with a rating of Buy and set a new price target of $19.00

    4/2/25 8:01:55 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Leadership Updates

    Live Leadership Updates

    View All

    OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor

    Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of OST-HER2 approval decisions expected by year-end 2026Upcoming FDA Pre-BLA meeting will focus on the use of recent seroconversion biomarker data as a key surrogate clinical efficacy endpoint to support a BLA for OST-HER2 under the Accelerated Approval ProgramCommercialization and reimbursement preparations well underway for the U.S., U.K., and Europe in parallel with ongoing partnership discussionsNew York, New York and Rockville, Maryland--(Newsfile Corp. - May 14, 2026) - OS Therapies, Inc. (NY

    5/14/26 7:30:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

    Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with listeria oncology pipeline prioritization, combinations with other oncology-focused biotechnologies and tADC candidate selection for further developmentNew York, New York--(Newsfile Corp. - April 13, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, announced today that Dr. Robert "Bob" S. Langer, co-founder of Moderna, was appointed to the Company's strategic advisory board. Dr. Langer will assist managemen

    4/13/26 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

    Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma regulatory advice and oncology pipeline prioritizationNew York, New York--(Newsfile Corp. - April 8, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that Craig Eagle, MD, was appointed to the Company's newly-formed strategic advisory board. The Company's strategic advisory board is being formed to assist the Company in fine-tuning its osteosarcoma regulatory execution plan and to help develop a detailed pipeline

    4/8/26 11:38:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Financials

    Live finance-specific insights

    View All

    OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

    Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the OST-HER2 approach. Participants will include strategic advisors Dr. Craig Eagle and Dr. Bob Langer, and Osteosarcoma key opinion leader Dr. Peter Anderson from Cleveland Clinic.EMA and Australia TGA (ATGA) align on 3-year overall survival as the approvable clinical efficacy endpoint for Conditional Marketing Authorizations (CMAs), with alignment also achieved on confirmatory Phase 3 initiation, initially only in Australia, planned for Q3 2026 to meet regulatory requirement to support early a

    4/30/26 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

    Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up meetings with EU EMA and Australian TGANew York, New York--(Newsfile Corp. - April 27, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that it will be hosting a conference call on Thursday April 30, 2026 at 8:30am ET to review the data that supported the recent Patent Cooperation Treaty (PCT) international application for a OST-HER2 pharmacodynamic biomarker1 (the "OST-HER2

    4/27/26 4:01:00 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

    New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference call later in April 2026 to review new biomarker signatureBiomarker signature meets pharmacodynamic/response criteria established by FDA's Biomarkers, EndpointS and other Tools (BEST) program for use as a surrogate clinical endpoint of 1-year event free survival and 2-year overall survival in OST-HER2's Phase 2b trial in the prevention of delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma to support a BLA submission under FDA's Accelerated Approval ProgramNew York, New York--(New

    4/16/26 7:20:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OS Therapies Incorporated

    SC 13G - OS Therapies Inc (0001795091) (Subject)

    8/28/24 4:30:09 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care